ARCHIVES

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

This article is from The Cancer Letter archive.

Vol. 31 No. 35 | September 30, 2005

Download PDF Visit The Full Archive

Related Articles

FDA To Expand Disclosure For Advisory Committee Members

April 23, 2010

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

New Jersey Legislature Votes to Oppose USPSTF PSA Screening Downgrade

January 20, 2012

Clinical Trials Approved By NCI CTEP During May

June 28, 2002

Donald Coffey Is President-Elect Of NCCR; Coalition Elects Five New Board.

January 28, 2000

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

January 27, 2012